News und Analysen
ICON Announces Appointment of New Chief Financial Officer
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Nigel Clerkin as its new Chief Financial Officer (CFO).
Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer
Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer (WCLC) from September 7
Destiny Pharma initiates research to explore XF drug potential for CF
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update
Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and
EQS-News: Eckert & Ziegler becomes European contract manufacturer for Telix's innovative Phase III ProstACT GLOBAL study
EQS-News: Formycon reports a strong first half-year with multiple milestones achieved
Savara Reports Second Quarter 2024 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2024 and
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults
Pfizer Inc. (NYSE: PFE) today announced positive top-line safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT (RSV IMmunizatiON Study
EQS-Adhoc: Subsidiaries of Vita 34 reach agreement with US licensor
EQS-News: Eckert & Ziegler Continues Sales and Earnings Growth in the First Half of 2024
Premier, Inc. Declares Quarterly Cash Dividend
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common
The Trust for the National Mall and Humana Announce New Programming and Advance Court Reservation Sign-up Date for National Mall of Pickleball 2024
In honor of National Pickleball Day, The Trust for the National Mall and Humana (NYSE: HUM) announce exciting program details for the three-day monumental event, National Mall of Pickleball
EQS-News: Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Kuros Biosciences Reports First Half of 2024 Results
STAAR Surgical Reports Second Quarter 2024 Results
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
Charles River Laboratories Announces Second-Quarter 2024 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2024. For the quarter, revenue was $1.03 billion, a decrease of 3.2% from $1.06
Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG® for the Treatment of Type 2 Diabetes in Japan
Regulatory News:
Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) and POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage
EQS-News: Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 5, 2024, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and second quarter 2024 financial results.
“Sangamo has demonstrated important progress
Inogen Announces Second Quarter 2024 Financial Results
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30
Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024
Vistagen (NASDAQ: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and
Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it has entered into a license agreement with Genentech, a member of the Roche Group, to develop intravenously
EQS-Adhoc: Formycon AG increases its outlook for the 2024 fiscal year
EQS-News: Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone